FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1938895800> ?p ?o ?g. }

• W1938895800 endingPage "9706" @default.
• W1938895800 startingPage "9706" @default.
• W1938895800 abstract "9706 Background: Anemia and neutropenia are common and serious side effects in chemotreated cancer patients. It negatively impacts their quality of life and questions their chemotherapy compliance. Literature has scarcely reported incidence numbers of both complications in Europe. Using a series of cross-sectional surveys, it has been proven possible to estimate the incidence of both conditions over time. Methods: Data were available from study surveys conducted in five European countries (France, Italy, Germany, Spain and United Kingdom) in 1999, 2000, 2001 and 2003, using the same Case Report Form (CRF). Details of one cycle out of all cycles of chemotherapy were recorded retrospectively in 41,114 cancer patients. Anemia was determined as hemoglobin levels <12, <10 or < 8 g/dL and Absolute Neutrophil Count (ANC) cut-off, measuring the neutropenia, was specified at <0.5 × 109/L with fever >38.2 C° for febrile neutropenia (FN). Logistic regression was used to investigate the effects of gender, age, country, chemotherapy type, outcome of cycle number and year of treatment with 95% confidence intervals (CI). Results: Anemia (hemoglobin <12 g/dL) was found in 67% of the cancer patients receiving chemotherapy. Severe anemia (Hb<8g/dL) occurred in 10% of the patients. The incidence was 50% in AML patients compared to only 4% in breast cancer patients. The frequency of anemia was significantly lower in the United Kingdom and higher in Germany. Comparing the results of the last survey (2003) with the first (1999), a two-fold increase in the use of as well blood transfusions as erythropoietins was observed. FN affected 70% of AML patients and averaged 19% in all other cancer types. Conclusions: Overall anemia <10 Hb/gL was found in 25% of the patients receiving chemotherapy. It was more frequent in men, in younger persons and in the initial cycle of the chemotherapy. Further research is required to better identify patients at high risk of anemia, particularly in the initial cycle, since adequate measures of prevention and/or treatment are readily available. Management of neutropenia remained fairly unchanged over the last years in Europe. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen" @default.
• W1938895800 created "2016-06-24" @default.
• W1938895800 creator A5011631797 @default.
• W1938895800 creator A5038989495 @default.
• W1938895800 creator A5062427393 @default.
• W1938895800 date "2004-07-15" @default.
• W1938895800 modified "2023-09-27" @default.
• W1938895800 title "Anemia and neutropenia in cancer patients receiving chemotherapy" @default.
• W1938895800 doi "https://doi.org/10.1200/jco.2004.22.90140.9706" @default.
• W1938895800 hasPublicationYear "2004" @default.
• W1938895800 type Work @default.
• W1938895800 sameAs 1938895800 @default.
• W1938895800 citedByCount "1" @default.
• W1938895800 countsByYear W19388958002023 @default.
• W1938895800 crossrefType "journal-article" @default.
• W1938895800 hasAuthorship W1938895800A5011631797 @default.
• W1938895800 hasAuthorship W1938895800A5038989495 @default.
• W1938895800 hasAuthorship W1938895800A5062427393 @default.
• W1938895800 hasConcept C120665830 @default.
• W1938895800 hasConcept C121332964 @default.
• W1938895800 hasConcept C121608353 @default.
• W1938895800 hasConcept C126322002 @default.
• W1938895800 hasConcept C141071460 @default.
• W1938895800 hasConcept C187212893 @default.
• W1938895800 hasConcept C2776694085 @default.
• W1938895800 hasConcept C2777063308 @default.
• W1938895800 hasConcept C2778248108 @default.
• W1938895800 hasConcept C2778850193 @default.
• W1938895800 hasConcept C2778917026 @default.
• W1938895800 hasConcept C530470458 @default.
• W1938895800 hasConcept C61511704 @default.
• W1938895800 hasConcept C71924100 @default.
• W1938895800 hasConcept C74133956 @default.
• W1938895800 hasConceptScore W1938895800C120665830 @default.
• W1938895800 hasConceptScore W1938895800C121332964 @default.
• W1938895800 hasConceptScore W1938895800C121608353 @default.
• W1938895800 hasConceptScore W1938895800C126322002 @default.
• W1938895800 hasConceptScore W1938895800C141071460 @default.
• W1938895800 hasConceptScore W1938895800C187212893 @default.
• W1938895800 hasConceptScore W1938895800C2776694085 @default.
• W1938895800 hasConceptScore W1938895800C2777063308 @default.
• W1938895800 hasConceptScore W1938895800C2778248108 @default.
• W1938895800 hasConceptScore W1938895800C2778850193 @default.
• W1938895800 hasConceptScore W1938895800C2778917026 @default.
• W1938895800 hasConceptScore W1938895800C530470458 @default.
• W1938895800 hasConceptScore W1938895800C61511704 @default.
• W1938895800 hasConceptScore W1938895800C71924100 @default.
• W1938895800 hasConceptScore W1938895800C74133956 @default.
• W1938895800 hasIssue "14_suppl" @default.
• W1938895800 hasLocation W19388958001 @default.
• W1938895800 hasOpenAccess W1938895800 @default.
• W1938895800 hasPrimaryLocation W19388958001 @default.
• W1938895800 hasRelatedWork W1196768483 @default.
• W1938895800 hasRelatedWork W1938895800 @default.
• W1938895800 hasRelatedWork W1975036198 @default.
• W1938895800 hasRelatedWork W2061928026 @default.
• W1938895800 hasRelatedWork W2316813997 @default.
• W1938895800 hasRelatedWork W2358410098 @default.
• W1938895800 hasRelatedWork W2416059376 @default.
• W1938895800 hasRelatedWork W3028396829 @default.
• W1938895800 hasRelatedWork W4231279047 @default.
• W1938895800 hasRelatedWork W4312909839 @default.
• W1938895800 hasVolume "22" @default.
• W1938895800 isParatext "false" @default.
• W1938895800 isRetracted "false" @default.
• W1938895800 magId "1938895800" @default.
• W1938895800 workType "article" @default.